Navigation Links
WuXi PharmaTech Announces Appointment of Walter Kwauk to Board
Date:8/8/2014

SHANGHAI, Aug. 8, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced the appointment of Walter Teh-Ming Kwauk as an independent director to the Board of Directors. Mr. Kwauk will serve on the Audit Committee. 

Mr. Kwauk is currently a senior consultant at Motorola Solutions (China) Co., Ltd. He serves as a director of Thunder Power Co. Ltd.; Sinosoft Technology Group Ltd., of which he serves as chairman of the audit committee; China Fordoo Holdings Ltd., of which he serves as chairman of the audit committee; and several private companies. He was formerly a director of Alibaba.com Ltd. Mr. Kwauk worked for KPMG from 1977 to 2002 and held a number of senior positions, including the general manager of KPMG's joint venture accounting firm in Beijing, the managing partner in KPMG's Shanghai office, and a partner in KPMG's Hong Kong office. He is a member of the Hong Kong Institute of Certified Public Accountants. Mr. Kwauk received a B.S. and a licentiate's degree in accounting from the University of British Columbia.

"I am very pleased to join the board of WuXi PharmaTech, a company well-known as a leader in pharmaceutical R&D services," said Mr. Kwauk. "I look forward to working with the other board members to help WuXi grow."

"We are delighted to have the benefit of Walter's experience in corporate governance and in accounting and auditing matters," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "With his help, WuXi will continue to advance in its mission to build a comprehensive, integrated open-access R&D services platform."

About WuXi PharmaTech

WuXi PharmaTech (NYSE: WX) is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For further information please contact:

Ronald Aldridge
Director of Investor Relations
+1-201-585-2048
ron_aldridge@wuxiapptec.com

Aaron Shi
Associate Director of Corporate Communications
+86-21-5046-4362
aaron_shi@wuxiapptec.com


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release
2. WuXi PharmaTech Provides Update of 2013 Financial Guidance, to Present at J.P. Morgan Healthcare Conference
3. Winners of WuXi PharmaTech Awards Inducted into Prestigious Academies
4. WuXi PharmaTech Presents 2013 Life Science and Chemistry Awards
5. WuXi PharmaTech to Partner with Pharmacyclics
6. WuXi PharmaTech Announces Third-Quarter 2013 Results
7. WuXi PharmaTech Announces Licensing Agreement for Patient-Derived Xenograft Models with Mayo Clinics Center for Individualized Medicine
8. Zacks.com featured expert Kevin Matras highlights: Core Laboratories NV, Invesco Ltd., Medtronic, Inc., Willbros Group Inc. and WuXi PharmaTech Inc.
9. WuXi PharmaTech Schedules First-Quarter 2013 Earnings Release
10. Breckenridge announces agreement with Aptalis Pharmatech to market Propranolol Hydrochloride Extended-Release Capsules
11. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... , May 19, 2016 ... titled, World Biopsy Devices Market Opportunities and Forecasts, ... devices market generated $1,621 million in 2015. The ... 2015, and is expected to maintain this trend ... http://photos.prnewswire.com/prnh/20140911/647229 ) , To ...
(Date:5/19/2016)... Calif. , May 19, 2016  Global Blood ... company developing novel therapeutics for the treatment of grievous ... new GBT440 data will be presented in a poster ... Congress in Copenhagen . The ... 1/2 GBT440-001 study in sickle cell disease (SCD), including ...
(Date:5/19/2016)... , May 19, 2016  IBM,s (NYSE:   IBM ... international study to identify drug candidates to cure Zika, ... has declared a global public health emergency. ...  anyone with a computer or Android device to join ... expertise or money to help; they simply  run an ...
Breaking Medicine Technology:
(Date:5/23/2016)... ... May 23, 2016 , ... ... research on discriminated minorities’ quality of life and is currently focusing on ways ... advocacy documentaries to be tested through research to find out whether watching them ...
(Date:5/23/2016)... (PRWEB) , ... May 23, ... ... and security executive networking and relationship-marketing firm, announced today that nominations will ... Information Security Executive® (ISE®) Northeast Awards. , Awards include the Information Security ...
(Date:5/23/2016)... San Francisco, California (PRWEB) , ... May 23, 2016 , ... ... that their organization of noteworthy California winemakers will close operations at the end of ... importance of balance in California wine,” Hirsch said. “As we look back on what ...
(Date:5/23/2016)... ... 23, 2016 , ... Hospice of Westchester (HOW), an organization ... 24 years, recently hosted its sixth annual Celebration of Life Memorial Butterfly Release. ... each concluding with the release of Monarch butterflies that honored the memories of ...
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... Octo Consulting ... to the federal government, is proud to announce they have recently won two awards ... International’s 2016 Small Business of the Year. Additionally, Octo VP of Civilian Affairs, ...
Breaking Medicine News(10 mins):